Treatment and survival of de novo HER2-positive metastatic breast cancer across regional cancer networks in the Netherlands: a cohort study

N Ding, SME Geurts, KEPE Hermans, IJH Vriens, R Visserman, LFS Kooreman, NAJB Peters, EM Heuts, J Verloop, AC Voogd, VCG Tjan-Heijnen · 2026

Read Treatment and survival of de novo HER2-positive metastatic breast cancer across regional cancer networks in the Netherlands: a cohort study by N Ding, SME Geurts, KEPE Hermans, IJH Vriens, R Visserman, LFS Kooreman, NAJB Peters, EM Heuts, J Verloop, AC Voogd, VCG Tjan-Heijnen (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13542605.txt.

Description

N Ding and co-authors compare care and survival for a fast-moving breast cancer type across Dutch regions, in a 2026 study. Targeted therapy has lifted survival for patients whose cancer had already spread at diagnosis. Registry data covered 2,158 such patients treated between 2013 and 2023 in seven regions.

First-line targeted therapy use ranged from 70 to 88 percent by region, but after adjusting for patient mix, only one region stood out. Raw median survival ranged widely, from about 43 to 75 months. After adjustment, no region's survival gap held firm. The authors conclude that care is broadly even across the country, and that raw survival gaps mostly reflect who the patients were, not how they were treated.

Catalog record

CREATORN Ding, SME Geurts, KEPE Hermans, IJH Vriens, R Visserman, LFS Kooreman, NAJB Peters, EM Heuts, J Verloop, AC Voogd, VCG Tjan-Heijnen
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE33 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13542605

Browse the full library · About the Tower of Babel